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Introduction: Chemotherapy-induced alopecia is one of the most common adverse events caused by conventional
cytotoxic chemotherapy, yet there has been very little progress in the prevention or treatment of this side effect.
Although this is not a life-threatening event, alopecia is very psychologically difficult for many women to manage.
In order to improve the quality of life for these women, it is important to elucidate the molecular mechanisms of
chemotherapy-induced alopecia and develop ways to effectively prevent and/or treat it. To identify the genetic risk
factors associated with chemotherapy-induced alopecia, we conducted a genome-wide association study (GWAS)
using DNA samples from breast cancer patients who were treated with chemotherapy.
Methods: We performed a case-control association study of 303 individuals who developed grade 2 alopecia, and
compared them with 880 breast cancer patients who did not show hair loss after being treated with conventional
chemotherapy. In addition, we separately analyzed a subset of patients who received specific combination
therapies by GWASs and applied the weighted genetic risk scoring (wGRS) system to investigate the cumulative
effects of the associated SNPs.
Results: We identified an SNP significantly associated with drug-induced grade 2 alopecia (rs3820706 in CACNB4
(calcium channel voltage-dependent subunit beta 4) on 2q23, P = 8.13 × 10-9, OR = 3.71) and detected several
SNPs that showed some suggestive associations by subgroup analyses. We also classified patients into four groups
on the basis of wGRS analysis and found that patients who classified in the highest risk group showed 443 times
higher risk of antimicrotubule agents-induced alopecia than the lowest risk group.
Conclusions: Our study suggests several associated genes and should shed some light on the molecular
mechanism of alopecia in chemotherapy-treated breast cancer patients and hopefully will contribute to
development of interventions that will improve the quality of life (QOL) of cancer patients.Introduction
Breast cancer is the most common malignancy among
women worldwide [1]. Although treatment of breast cancer
has been significantly improved by the development of
molecular-targeted drugs in the past few decades, a subset
of patients do not receive benefit from these modalities* Correspondence: ynakamura@bsd.uchicago.edu
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reproduction in any medium, provided the or[2,3]. Such patients and the majority of relapsed patients
are treated with conventional cytotoxic chemotherapy that
can often cause various adverse events including hair loss.
Hair loss (alopecia) is one of the most common side
effects caused by chemotherapy in cancer patients,
particularly in women with breast cancer. Although
molecular-targeted drugs such as trastuzumab do not
cause alopecia, these drugs are given together with other
chemotherapeutic agents. Most of the cytotoxic agents
cause alopecia, but the severity in individual patients
and the incidence by the types of drugs are significantly
different: more than 80% of patients treated with
antimicrotubule agents, more than 60% of those withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inhibitors, and 10 to 50% of those with antimetabolite-
based drugs experience severe alopecia [4]. It is also well
known that the incidence and the severity are increased
when patients are treated with a combination of multiple
drugs rather than a single agent [4,5]. Usually, hair loss
begins one to two weeks after the start of chemotherapy
and a patient’s hair can be completely lost in a one- to
two-month period. Hair starts to regrow after chemother-
apy is completed or discontinued [6,7]. This drug-induced
hair loss is not a life-threatening side effect, however, it
can strongly influence cosmetic appearance and psy-
chological stresses, and often affects the quality of life
(QOL) of the patients [7]. Several studies have demon-
strated that the majority of women patients are distressed
due to treatment-related alopecia and that 8% of the
women avoid chemotherapy because they are unwilling to
deal with hair loss [7-10]. Moreover, one study reported
that the hair loss was harder to manage than the loss of a
breast in some patients [11].
It is known that there are three cycles during hair
growth: anagen is the growth phase; catagen is the invo-
luting or regressing phase; and telogen is the resting or
quiescent phase [12,13]. It is thought that chemotherapeu-
tic agents target highly proliferative hair matrix cells in the
anagen phase, called the anagen effluvium [4,14], but
the molecular mechanism is still largely unknown. Scalp
cooling with cold air or liquid is the most widely used
method since the 1970s to prevent or minimize drug-
induced alopecia. However, it is not always effective and it
is not easy to standardize the system of scalp cooling [4,15].
Since medications such as minoxidil or AS101, which
are widely used for aging-related hair loss, failed to show
any protective effect in the case of chemotherapy-induced
alopecia [16-19], there is currently no good option to
prevent or treat drug-induced alopecia.
In this study, we conducted a genome-wide association
study (GWAS) using mono- or combination-chemother-
apy-treated breast cancer cases to identify common genetic
factors that are associated with drug-induced alopecia. We
have identified some loci that are likely to be associated
with increased risk of chemotherapy-induced alopecia.
These results can provide new insight into the molecular
mechanisms of hair loss induced by anticancer drugs and
may contribute to development of drugs that can prevent
or treat this emotionally devastating side effect.
Methods
Participants
All samples used in this study were obtained from the
BioBank Japan located at the Institute of Medical Science
at the University of Tokyo. The BioBank Japan project
[20], which began in 2003, is a collaborative network
of 66 hospitals in Japan [21]. The project achieved acollection of genomic DNA, serum, and clinical informa-
tion from a total of 330,000 cases (200,000 patients)
that had at least 1 of 47 defined diseases. Adverse drug
reaction (ADR) information was collected from the
patients’ medical records by medical coordinators. From
the BioBank Japan, we selected 1,367 individuals who had
been diagnosed with breast cancer and had received
conventional chemotherapy. Of them, 303 patients had
experienced grade 2 alopecia (ADR), 184 revealed grade 1
alopecia, and the remaining 880 patients were reported to
have had no alopecia (non-ADR). Grade 2 alopecia is
defined as complete hair loss, which is the most severe
grade in this adverse reaction (National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 3.0). In
addition, samples from 23 breast cancer patients with
grade 2 alopecia were collected at the Tokushima Breast
Care Clinic to further verify the findings of the initial
GWAS study; all of the 23 patients were treated with a
combination therapy of docetaxel and cyclophospha-
mide. The detailed clinical information is summarized in
Additional file 1. All participants provided written
informed consent. This project was approved by the
Institutional Review Board of the Institute of Medical
Science, the University of Tokyo, and RIKEN Center for
Genomic Medicine.
Genotyping and quality control
For GWAS, all DNA samples were genotyped using
Illumina Human OmniExpress BeadChip kits (Illumina, San
Diego, CA, USA). Sample quality control was performed
by identity-by-state clustering across all samples to evaluate
cryptic relatedness for each sample and by use of principal
component analysis to exclude genetically heterogeneous
samples from further analysis. We applied SNP quality con-
trol by excluding SNPs with a call rate of <0.99, a P value
of the Hardy-Weinberg equilibrium test of ≤1.0 × 10-6, and
non-polymorphic SNPs in the dataset. Quantile-quantile
(Q-Q) plots and lambda values, which were used for fur-
ther evaluation of population substructure, were calculated
between observed P value from Fisher’s exact test allelic
model against expected P value. For genotyping of add-
itional samples, we used the multiplex PCR-based Invader
assay (Third Wave Technologies, Madison, WI, USA) as
described previously [22].
Statistical analysis
In the GWAS, Fisher’s exact test was applied to three
genetic models: an allele frequency model, a dominant
inheritance model, and a recessive inheritance model.
SNPs were rank-ordered according to the lowest P value
among the three models. Odds ratio (OR) and confidence
intervals (CIs) were calculated for the allelic model using
a non-risk allele or a non-risk genotype as a reference. A
Manhattan plot was generated by using the minimum
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analysis, the genotype count of the additional samples
was added to that of the GWAS. All statistical analyses
and plots were carried out using R statistical environ-
ment version 2.13.2 [23], and PLINK version 1.07
[24,25]. Haploview software was used for haplotype
analysis, to draw the Manhattan plot and linkage
disequilibrium (LD) map.
Scoring system using weighted genetic risk score (wGRS)
The scoring analysis was performed by utilizing SNPs
with P min of <1.0 × 10-5 after exclusion of SNPs that
show strong LD (r2 >0.8) of each GWAS. wGRSs were
calculated according to a method reported by De Jager
et al. [26]. Briefly, we first determined the effect size of
each SNP, calculated the cumulative genetic risk scores
by multiplying the number of risk alleles for each SNP
by its corresponding weight, and subsequently took the
sum across the total number of SNPs that were taken
into consideration of each GWAS set. We classified the
genetic risk score into four different groups, which were
created from the mean and standard deviation (SD) as
follows: <mean −1 SD for group 1; mean −1 SD to average
for group 2; average to mean +1 SD for group 3; >mean +1
SD for group 4. Odds ratio (OR), 95% confidence interval
(CI), P value, sensitivity, and specificity were calculated
using group 1 as reference.
Results
Genome-wide association for chemotherapy-induced
alopecia in breast cancer
We performed a GWAS of 303 individuals who developed
grade 2 alopecia, and compared them with 880 breast
cancer patients who did not show any hair loss after
being treated with conventional chemotherapy. The Q-Q
plot and lambda (λ) value (λ <1.000) indicated no evidence
of population stratification between the cases and controls
we analyzed (Additional file 2). After the data was quality
controlled, association analysis was carried out for 555,600
autosomal SNPs by Fisher’s exact test on the basis of three
genetic models: allelic-effect, dominant-inheritance, and
recessive-inheritance models. Among the SNPs analyzed
in the GWAS, we identified a locus that reached genome-
wide significance (rs3820706 near CACNB4, minimum
P = 8.13 × 10-9, ORrec = 3.71, 95% CI: 2.24 to 6.15) and
five additional loci that revealed suggestive association
with chemotherapy-induced alopecia with a P value of
<10-6 (Additional file 3 and Table 1). We further validated
the top nine SNPs that revealed the smallest P value
on the three loci in the GWAS result, using 23 addition-
ally obtained alopecia cases. The combined analysis
slightly improved the association with the rs3820706 locus
(combined minimum P = 1.85 × 10-9, ORrec = 2.38,
95% CI: 1.44 to 3.93) and a nearby SNP rs16830728(combined minimum P = 2.60 × 10-8, ORrec = 3.61,
95% CI: 2.17 to 5.98; Table 2). As these two SNPs are
in strong LD with r2 of >0.8, we performed haplotype
analysis, but the association was not as strong as
those of single SNPs (Additional file 4 and Additional
file 5).
Association studies for drug subgroups and specific drugs
We also performed subgroup analyses for different types
of chemotherapy, namely the CEF (cyclophosphamide +
epirubicin +/− 5-FU)-treated and CAF (cyclophospha-
mide + doxorubicin +/− 5-FU)-treated groups. Detailed
sample demographics are described in Additional file 1.
In the GWAS of the CEF-treated group, genetic variants
in the ALOX5AP gene on chromosome 13 were most sig-
nificantly associated with chemotherapy-induced alopecia
(rs3885907, minimum P = 1.38 × 10-6, OR = 2.66, 95% CI:
1.71 to 4.13). The GWAS analysis for the CAF-treated
group identified SNP rs594206 located in an intronic
region of BCL9 on chromosome 1 to be most strongly
associated (minimum P = 5.91 × 10-7, OR = 36.3, 95%
CI: 4.58 to 287; Additional file 3 and Additional file 6).
Although the P values for these variants did not exceed
the genome-wide significance, it is notable that OR for
the identified SNP for the CAF analysis is very large. In
addition, we analyzed the association with antimicrotubule
agents, paclitaxel monotherapy and docetaxel monother-
apy because of their high incidence of alopecia, and found
that rs1858231 (minimum P = 1.95 × 10-6, OR = 2.71, 95%
CI: 1.79 to 4.12), rs11059635 (minimum P = 2.05 × 10-7,
OR = 6.63, 95% CI: 2.95 to 14.9) and rs4262906 (minimum
P = 6.62 × 10-7, OR = 4.36, 95% CI: 2.41 to 7.89) were most
significantly associated, respectively (Additional file 6).
SNP rs3820706 on CACNB4, which showed the strongest
association with chemotherapy-induced alopecia with the
genome-wide significance in the analysis of all-combined
samples, showed modest associations in all of the subgroup
analyses (Additional file 7). Although the numbers of sam-
ples in these subgroup analyses were relatively limited,
these data may provide fundamental information that will
contribute to a better understanding of chemotherapy-
induced alopecia.
Scoring system for prediction of chemotherapy-induced
alopecia
We then evaluated the cumulative effects of the candidate
loci (SNPs showing P <10-5 in Table 1 and Additional file 6)
using a weighted genetic risk scoring (wGRS) method [26].
We first selected eight SNPs from the GWAS of the com-
bination of all samples and calculated wGRS. As shown in
Additional file 8, only 17 of 190 patients belonging to
group 1 showed severe hair loss (grade 2) while 54 of 82
patients in group 4 revealed it. Cumulative risk scores for
the risk of drug-induced alopecia were calculated to be
Table 1 Summary of association results of the genome-wide association study
ADRb Non-ADRc RAF P value
CHR SNP Gene Allele 1/2 (risk) 11 12 22 11 12 22 ADR Non-ADR Allelic Dominant Recessive ORa 95% CI
2 rs3820706 CACNB4 A/G (G) 18 169 116 167 421 291 0.66 0.57 8.26E-05 1.07E-01 8.13E-09 3.71 (2.24-6.15)
2 rs6725180 CACNB4 A/C (C) 17 152 134 135 429 316 0.69 0.60 7.90E-05 1.11E-02 3.84E-06 3.05 (1.81-5.14)
8 rs16908658 FAM135B G/A (G) 30 93 180 23 286 571 0.25 0.19 1.07E-03 9.68E-02 9.93E-07 4.09 (2.34-7.17)
10 rs7476422 PCDH15 T/G (G) 4 47 252 34 245 601 0.91 0.82 1.20E-07 3.77E-07 3.58E-02 2.17 (1.60-2.93)
10 rs857373 PCDH15 G/A (A) 5 55 243 43 255 581 0.89 0.81 5.16E-07 3.15E-06 1.11E-02 2.00 (1.51-2.66)
10 rs857392 PCDH15 G/A (A) 5 55 243 42 252 584 0.89 0.81 9.08E-07 5.95E-06 1.60E-02 1.97 (1.48-2.62)
10 rs1319836 PCDH15 C/T (T) 5 55 243 42 254 583 0.89 0.81 9.10E-07 4.34E-06 1.60E-02 1.98 (1.49-2.63)
10 rs7919725 PCDH15 A/G (G) 5 56 242 42 256 580 0.89 0.81 9.94E-07 4.68E-06 1.60E-02 1.97 (1.48-2.60)
10 rs857369 PCDH15 T/C (C) 1 32 270 18 178 684 0.94 0.88 2.29E-06 7.25E-06 5.87E-02 2.33 (1.60-3.39)
10 rs9416306 PCDH15 G/T (T) 1 32 270 18 178 682 0.94 0.88 2.29E-06 7.13E-06 5.88E-02 2.34 (1.61-3.39)
10 rs1219862 PCDH15 C/T (T) 2 31 270 17 182 681 0.94 0.88 2.73E-06 5.08E-06 1.85E-01 2.28 (1.58-3.30)
13 rs7318267 FARP1 C/T (T) 11 149 143 108 387 385 0.72 0.66 6.69E-03 3.15E-01 4.09E-06 3.71 (1.97-7.01)
13 rs2282048 FARP1 T/C (C) 11 148 144 107 387 386 0.72 0.66 5.72E-03 2.84E-01 6.24E-06 3.68 (1.95-6.93)
17 rs1530357 LOC100506974 A/G (A) 57 170 76 114 417 349 0.47 0.37 1.11E-05 4.29E-06 1.39E-02 1.96 (1.45-2.63)
17 rs1530361 LOC100506974 A/G (A) 53 165 85 99 408 372 0.45 0.35 8.83E-06 1.12E-05 7.04E-03 1.54 (1.27-1.86)
19 rs11666971 LASS4 G/A (G) 46 119 138 56 379 445 0.35 0.28 1.64E-03 1.43E-01 8.13E-06 2.63 (1.74-3.96)
aORs and CIs are calculated according to the associated genetic model; bindividuals who developed grade 2 alopecia; cindividuals who did not developed any ADRs after chemotherapy. CHR, chromosome; SNP, single














Table 2 Summary of combined results of the genome-wide association study and additional genotyped data
ADRc Non-ADRd P value
SNP CHR Chromosome positiona Gene Allele 1/2 (risk) 11 12 22 RAF 11 12 22 RAF Allelic Dominant Recessive P min ORb (95% CI)
rs3820706 2 152957411 CACNB4 A/G GWAS 18 169 116 0.66 167 421 291 0.57 8.26E-05 1.07E-01 8.13E-09 8.13E-09 3.71
(2.24-6.15)
(G) 2nd 1 12 10 0.70 167 421 291 0.57 9.80E-02 3.70E-01 1.00E-01 9.80E-02 1.72
(0.91-3.25)
Combine 19 181 126 0.66 167 421 291 0.57 3.16E-05 7.65E-02 1.85E-09 1.85E-09 2.38
(1.44-3.93)
rs16830728 2 152981335 STAM2 G/T GWAS 17 163 123 0.68 153 422 304 0.59 1.11E-04 6.16E-02 7.24E-08 7.24E-08 3.54
(2.11-5.96)
(T) 2nd 1 11 11 0.72 153 422 304 0.59 9.40E-02 1.91E-01 1.55E-01 9.40E-02 1.79
(0.94-3.43)
Combine 18 174 134 0.68 153 422 304 0.59 3.49E-05 4.30E-02 2.60E-08 2.60E-08 3.61
(2.17-5.98)
rs7476422 10 56204291 PCDH15 T/G GWAS 4 47 252 0.91 34 245 601 0.82 1.20E-07 3.77E-07 3.58E-02 1.20E-07 2.17
(1.60-2.93)
(G) 2nd 0 7 16 0.85 34 245 601 0.82 8.45E-01 1.00E+00 1.00E+00 8.45E-01 1.21
(0.53-2.72)
Combine 4 54 268 0.91 34 245 601 0.82 2.63E-07 1.15E-06 2.41E-02 2.63E-07 2.06
(1.54-2.75)
aOn the basis of NCBI 36 genome assembly; bORs and CIs are calculated according to the associated genetic model; cindividuals who developed grade 2 alopecia; dindividuals who did not developed any ADRs after
chemotherapy. The same controls were used in the GWAS and second stages analysis. SNP, single nucleotide polymorphism; CHR, chromosome; ADR, adverse drug reaction; RAF, risk allele frequency; P min, minimum
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CI: 2.62 to 7.53; P = 1.44 × 10-21, 95% CI: 9.99 to 38.6,
respectively), compared with patients in group 1.
Similarly, in the subgroup analysis, an individual be-
longing to group 4 with the highest risk score in each of
the CEF, CAF, antimicrotubules, paclitaxel, and docetaxel
analyses was estimated to have 86.2 times, 891 times, 858
times, 1,680 times, and 441 times higher risk for the
drug-related alopecia than those in group 1, respectively
(Additional file 8). Due to the clinical importance of
antimicrotubule agents (paclitaxel and docetaxel), which
cause chemotherapy-induced alopecia at nearly 80% fre-
quency, we further investigated the wGRS scoring method
using cases with grade 1 alopecia. Interestingly, the associ-
ation levels and odds ratios of patients with grade 1 alopecia
induced by the antimicrotubule agents were intermediate,
compared with those of grade 2 alopecia (Table 3). Not
only antimicrotubule agents, but other subgroups (all, CEA
or CEF) also showed similar results, and the association
level of grade 1 was intermediate compared with grade 2.
These results further support a possible association of
these variants in alopecia development (Additional file 9).
As shown in Figure 1, the proportion of grade 2 alopecia
increased according to the increase of the wGRS score; for
example, in the case of docetaxel, only one (3.4%) of the
29 patients in group 1 revealed grade 2 alopecia, while 52Table 3 wGRS results of antimicrotubule agents, docetaxel, a
Cat Score G2a G1b G0c %-G2 %-G1 %
Antimicrotubule (6 SNPs)
1 <5.56 2 7 34 0.05 0.16
2 5.56-7.60 25 20 50 0.26 0.21
3 7.60-9.63 65 17 19 0.64 0.17
4 >9.63 26 6 1 0.79 0.18
Total 118 50 104
Docetaxel (4 SNPs)
1 <2.26 1 5 23 0.03 0.17
2 2.26-4.70 9 6 14 0.31 0.21
3 4.70-7.15 33 5 4 0.79 0.12
4 >7.15 19 2 0 0.90 0.10
Total 62 18 41
Paclitaxel (7 SNPs)
1 <3.24 2 4 28 0.06 0.12
2 3.24-7.48 4 14 22 0.10 0.35
3 7.48-11.7 35 12 11 0.60 0.21
4 >11.7 16 5 0 0.76 0.24
Total 57 35 61
aIndividuals who developed grade 2 alopecia; bindividuals who developed grade 1
dORs and CIs are calculated using category (group) 1 as reference. *OR calculated a
any of the cell expectations would cause a division by zero error. Cat, category; OR,(83%) of 63 patients belonging to groups 3 and 4 developed
grade 2 alopecia. These results indicate that our scoring
system may be applied to predict severe chemotherapy-
induced alopecia and might provide useful information for
better understanding of the hair-loss mechanism, even
though further verification using an additional independent
set(s) of samples is warranted.
Finally, we simulated the sample number that is re-
quired to verify our scoring system. In BioBank Japan,
a total of 279 patients received antimicrotubule agents
(paclitaxel and/or docetaxel). Among them, 119 (43%)
patients developed grade 2 alopecia, 55 (20%) developed
grade 1 alopecia and 105 (37%) did not show any adverse
events. Among 156 patients who received paclitaxel
monotherapy, 57 (37%) developed grade 2 alopecia, 36
(23%) developed grade 1 alopecia and 63 (40%) did not
develop any adverse reactions. When we assume that
100 patients who receive antimicrotubule agents (or
paclitaxel monotherapy) are registered, the incidences of
alopecia are estimated as shown in Table 4. If we categorize
the patients by wGRS according to the data in Table 3, 100
additional patients should provide the sufficient statistical
power to verify our results with P value of <0.01. Even if
two individuals in each of groups 1 and 4 are not correctly
predicted, the calculated P value is still 0.001 by Fisher’s
exact test.nd paclitaxel-induced alopecia
-G0
G2 vs. G0 G1 vs. G0
ORd* 95%CI P value ORd* 95%CI P value
0.79 Ref Ref
0.53 8.50 1.89-38.3 1.66E-03 1.94 0.74-1.42 2.52E-01
0.19 58.2 12.8-265 4.93E-14 4.35 1.53-12.4 6.42E-03
0.03 442 38.0-5140 2.71E-14 29.1 3.02-282 8.39E-04
0.79 Ref Ref
0.48 14.8 1.69-130 4.39E-03 1.97 0.51-7.68 4.88E-01
0.10 190 19.9-1810 1.01E-11 5.75 1.12-29.4 4.08E-02
0.00 611 23.5-15900 2.50E-11 21.4 0.89-511 4.83E-02
0.82 Ref Ref
0.55 2.55 0.43-15.2 4.01E-01 4.46 1.28-1.92 2.60E-02
0.19 44.6 9.12-218 9.55E-10 7.64 2.02-28.9 2.30E-03
0.00 376 17.0-8320 1.54E-10 69.7 3.26-1490 2.89E-04
alopecia; cindividuals who did not developed any ADRs after chemotherapy;
fter Haldane’s correction: adding 0.5 to all the cells of a contingency table if



































































































(34) (40) (58) (21) (29) (29) (42) (21) 
Figure 1 The proportions of patients by alopecia grade in each weighted genomic risk score. The proportions of patients who developed
no adverse reaction (G0), grade 1 alopecia, or grade 2 alopecia in each of the weighted genomic risk score (wGRS) groups. The number in
parentheses indicates the number of samples in each group. (A) paclitaxel monotherapy, (B) docetaxel monotherapy.
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Recent pharmacogenomics studies focus on prediction
of drug response as well as the risk assessment of toxic
events due to administration of drugs. Whole-genome
association studies have been proven to be a powerful
strategy to identify genetic factor(s) associated with various
adverse reactions caused by certain drugs. In this study,
we conducted the first GWAS for chemotherapy-induced
alopecia in Japanese breast cancer patients, and identified
one locus including two SNPs, rs3820706 on chromosome
2q23 and its nearby SNP rs16830728, which showed a
strong association with genome-wide significance, and
found several SNPs showing suggestive associations.
SNP rs3820706 is located near a gene encoding calcium
channel voltage-dependent subunit beta 4 (CACNB4), a
member of a beta subunit family of the voltage-dependentTable 4 Estimation of required sample number for verificatio
Cat












*P values are calculated by Fisher’s exact test. Cat, category; OR, odds ratio; CI, confcalcium channel (VDCC) complex. Calcium (Ca2+) func-
tions as a second messenger in many cellular signal trans-
duction pathways such as cell proliferation and apoptosis.
When VDCC is activated it depolarizes membrane po-
tentials, it allows Ca2+ to enter into cells [27]. We are
not aware of any previous reports indicating that there is a
relationship between the Ca2+ channel and alopecia. How-
ever, a potassium channel opener, minoxidil, was approved
for the treatment of alopecia by the US FDA in 1988 [28]
and has proven to be effective in a subset of alopecia
patients. Although the mode of action of minoxidil is
still not well known, the clinical outcome implies the
involvement of ion channels for K+ and probably Ca2+ in
the pathogenesis of alopecia. Intriguingly, the second most
significantly associated locus that we found in our study is
a region containing the PCDH15 gene on chromosomen
G2 G0 OR 95% CI P value*
1 12 Ref
9 18 6.00 0.67-53.7 1.24E-01
24 7 41.1 4.53-374 2.48E-05
9 1 108 5.92-1970 1.15E-04
43 38
1 18 Ref
3 15 3.60 0.34-38.3 3.40E-01
23 7 59.1 6.66-525 8.02E-07
10 0 259 9.66-6950 5.49E-07
37 40
idence interval; Ref, reference.
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which is involved in calcium-dependent cell-cell adhesion.
Additionally, among the 70 loci in the top 100 SNPs found
in our GWAS study, five loci are implicated to be ion
channels or proteins related to ion channels (data not
shown). Ion channels have shown to have important roles
not only in cell maintenance but also in stem/progenitor
cells [29]. Because cytotoxic agents damage the proliferat-
ing progenitor cells in the hair matrix [13], we suspect that
several ion channels might be involved in chemotherapy-
induced alopecia and be promising targets for development
of novel treatments.
However, since rs3820706 is strongly linked to
rs16830728, which is located within a gene encoding a
signal transducing adaptor molecule 2 (STAM2), we
cannot exclude the possibility that STAM2 is a candidate
gene for chemotherapy-induced alopecia. STAM2 is a
member of the STAM family, which is an adaptor protein
involved in the downstream signaling of cytokine receptors
that contain an SH3 domain and the immunoreceptor
tyrosine-based activation motif (ITAM). STAM2 is involved
in the signaling through GM-SCF and IL-2 stimulation,
and has a crucial role in T cell development [30,31]. As
most studies of STAM2 focused on immune cells, its
functions in other cell types like hair follicle cells are
not fully understood.
In addition, we performed subgroup analyses in which
we identified multiple loci that might be associated
with drug-induced alopecia. rs3885907, which was most
significantly associated in CEF-treated patients, was lo-
cated in an intron of ALOX5AP. ALOX5AP, arachidonate
5-lipoxygenase-activating protein, is related to the inflam-
matory responses and possibly to vascular diseases [32,33].
Detailed biological mechanisms in hair growth cycle are
not well characterized, but one paper reported involvement
of the ALOX5AP upregulation in scarring alopecia [34].
According to GWAS, for alopecia areata [35] that identi-
fied genes related in both innate and adaptive immunity,
inflammatory or immune responses seem to be important
in alopecia development. The mechanisms of hair loss in
alopecia areata and in drug-induced alopecia may not be
same, but our result suggests a possible relationship of the
immune response with chemotherapy-induced alopecia.
A SNP in the BCL9 gene was most significantly associ-
ated with hair loss in the CAF-treated group with very
high OR of 36.3. The BCL9 gene encodes B-cell lymph-
oma 9 which was reported to interact with β-catenin. The
β-catenin signaling pathway is involved in hair follicle
morphogenesis during embryogenesis and, interestingly,
hair is completely lost when β-catenin is depleted even
after hair follicles have been formed [36,37]. Similarly,
CDH7, one of the cadherin family members, showed an
association with severe hair loss in the CAF-treated group
with high OR of 32.5. This cadherin has been reported tobe expressed in hair follicles and regulate hair growth
[38,39]. These results, in combination with our GWAS
results, imply possible roles for BCL9 and CDH7 in
chemotherapy-induced alopecia. If so, these two molecules
as well as CACNB4 and other ion channel proteins could
be promising targets for the development of new treat-
ments. However, further validation is still needed.
Our approach of using retrospective BioBank samples
is not ideal for addressing this type of clinical problem
and certainly a prospective analysis with well-defined
clinical information would reduce the possibility of false-
positive and false-negative results. However, considering
the rapid progress of drug development or new combin-
ation therapies in recent years, it may not be wise to spend
lots of effort, time and budget to do a prospective study,
because the investigated regimen may not be used years
later when the research results come out. One of the
ways to effectively use the data and samples from the
retrospective study is shown by the application of our
wGRS system. The wGRS system indicated cumulative
effect of multiple genetic variants for alopecia predic-
tion. For example, the patients in group 4 who received
paclitaxel showed 376 times increased risk of alopecia,
compared with those belonging to group 1. Similarly, the
patients in group 4 who received docetaxel showed 611
times higher risk of alopecia than those belonging to group
1. We understand the disadvantages and pitfalls of the
retrospective design for the pharmacogenomics study such
as the higher risk of false results. However, considering the
very high OR obtained by the wGRS system, the advantage
of this approach is that we are able to verify the results by
using a relatively small number of additional prospective
samples. We simulated the sample size needed to verify
our results, as shown in Table 4, and suggest that the
statistical power should be sufficient to validate with
this small number of samples. We recognize that the
clinical utility for this wGRS may not be as high as in
other studies looking at life-threatening adverse events.
However, identification of genetic factors associated
with drug-induced hair loss should be the first step to
understand the molecular mechanism and to contribute
to the development of new drugs to prevent or treat
alopecia.
For many years, breast cancer patients have had to
accept the psychologically stressful side effect of alopecia
caused by cytotoxic chemotherapies. It is known that a
subset of patients will refuse to have chemotherapy be-
cause they do not want to lose their hair and therefore
may lose the opportunity to receive the benefit of the
chemotherapy and a chance to be cured of their disease.
The QOL of these patients is extremely important and we
believe it is urgent that we work to develop new treatment
or prevention strategies to manage chemotherapy-induced
alopecia. Although further validation of our findings is
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alterations in genes such as ion channel-related genes and
genes in the β-catenin signaling pathway. We welcome
other groups to examine and validate our results and
hope these findings will contribute to the development
of interventions that will improve the quality of life (QOL)
of breast cancer patients.Conclusions
In summary, we identified strongly associated genetic
variants near gene CACNB4 and several suggestively
associated SNPs with chemotherapy-induced alopecia in
breast cancer patients. These results provide new informa-
tion of the pathogenesis of chemotherapy-induced alopecia.Additional files
Additional file 1: Table S1. Patients’ characteristics.
Additional file 2: Quantile-quantile plot of the genome-wide
association study.
Additional file 3: Manhattan plot of the genome-wide association
study for chemotherapy-induced alopecia in breast cancer.
Additional file 4: Haplotype analysis.
Additional file 5: Table S2. Haplotype analysis of two SNPs.
Additional file 6: Table S3. Summary of genome-wide association
study for chemotherapy-induced alopecia with each drug subgroup
(P <10-6).
Additional file 7: Table S4. Association of rs3820706 in subgroups.
Additional file 8: Table S5. Weighted genomic risk score of each
genome-wide association study for chemotherapy-induced alopecia.
Additional file 9: Table S6. Weighted genomic risk score results of all,
CAF- and CEF-induced alopecia.Abbreviations
ADR: Adverse drug reaction; CAF: Cyclophosphamide + doxorubicin +/− 5-
FU; CEF: Cyclophosphamide + epirubicin +/− 5-; CI: Confidence interval;
GWAS: Genome-wide association study; LD: Linkage disequilibrium; OR: Odds
ratio; QOL: Quality of life; QQ plot: Quantile-quantile plot; SD: Standard
deviation; SNP: Single nucleotide polymorphism; wGRS: Weighted genomic
risk score.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YN planned and supervised the study and obtained funding. SC and SKL
designed the experiments and performed the GWAS and combined analysis.
SKL performed the wGRS and statistical analysis. HZ and MS collected
additional samples and medical information. MK genotyped all BioBank
Japan samples. AT performed sample quality control. YN, SC and SKL wrote
the manuscript. All authors revised and approved the manuscript for
publication.
Acknowledgements
We express our heartfelt gratitude to all the participants. We thank Miss
Kumi Matsuda for her outstanding technical assistance. We also thank all
other members and staff for their contribution to the sample collection. This
study was supported by a leading project of the Ministry of Education,
Culture, Sports, Science and Technology of Japan.Author details
1Department of Medicine, The University of Chicago, 5801 South Ellis
Avenue, Chicago, IL 60637, USA. 2Department of Surgery, The University of
Chicago, A27 S Maryland Avenue, Chicago, IL 60637, USA. 3Laboratory for
Statistical Analysis, Center for Genomic Medicine, 1-7-22 Suehiro-cho,
Tsurumi-ku, Yokohama, Kanagawa 230–0045, Japan. 4Laboratory for
Genotyping Development, Center of Genomic Medicine, 1-7-22 Suehiro-cho,
Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan. 5Tokushima Breast Care
Clinic, 4-7-7, Nakashimada-cho, Tokushima 770-0052, Japan. 6Laboratory of
Molecular Medicine, Human Genome Center, Institute of Medical Science,
The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639,
Japan.
Received: 1 May 2013 Accepted: 18 July 2013
Published: 11 September 2013References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics,
2008. CA Cancer J Clin 2008, 58:71–96.
2. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J
Med 2009, 360:790–800.
3. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A: Triple-negative breast
cancer: molecular features, pathogenesis, treatment and current lines of
research. Cancer Treat Rev 2010, 36:206–215.
4. Trueb RM: Chemotherapy-induced alopecia. Semin Cutan Med Surg 2009,
28:11–14.
5. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N: Single agent
versus combination chemotherapy for metastatic breast cancer.
Cochrane Database Syst Rev 2009, 2:CD003372.
6. Batchelor D: Hair and cancer chemotherapy: consequences and nursing
care–a literature study. Eur J Cancer Care (Engl) 2001, 10:147–163.
7. McGarvey EL, Baum LD, Pinkerton RC, Rogers LM: Psychological sequelae
and alopecia among women with cancer. Cancer Pract 2001, 9:283–289.
8. Tierney AJ, Taylor J, Closs SJ: Knowledge, expectations and experiences of
patients receiving chemotherapy for breast cancer. Scand J Caring Sci
1992, 6:75–80.
9. Munstedt K, Manthey N, Sachsse S, Vahrson H: Changes in self-concept
and body image during alopecia induced cancer chemotherapy.
Support Care Cancer 1997, 5:139–143.
10. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G,
Verweij J: Patient perceptions of the side-effects of chemotherapy: the
influence of 5HT3 antagonists. Br J Cancer 1997, 76:1055–1061.
11. Freedman TG: Social and cultural dimensions of hair loss in women
treated for breast cancer. Cancer Nurs 1994, 17:334–341.
12. Stenn KS, Paus R: Controls of hair follicle cycling. Physiol Rev 2001, 81:449–494.
13. Paus R, Haslam IS, Sharov AA, Botchkarev VA: Pathobiology of
chemotherapy-induced hair loss. Lancet Oncol 2013, 14:e50–e59.
14. Chon SY, Champion RW, Geddes ER, Rashid RM: Chemotherapy-induced
alopecia. J Am Acad Dermatol 2012, 67:e37–e47.
15. Grevelman EG, Breed WP: Prevention of chemotherapy-induced hair loss
by scalp cooling. Ann Oncol 2005, 16:352–358.
16. Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, Trancik RJ,
Bandstra BA, Compton LD: A randomized trial of minoxidil in chemotherapy-
induced alopecia. J Am Acad Dermatol 1996, 35:74–78.
17. Granai CO, Frederickson H, Gajewski W, Goodman A, Goldstein A, Baden H:
The use of minoxidil to attempt to prevent alopecia during chemotherapy
for gynecologic malignancies. Eur J Gynaecol Oncol 1991, 12:129–132.
18. Rodriguez R, Machiavelli M, Leone B, Romero A, Cuevas MA, Langhi M, Romero
Acuna L, Romero Acuna J, Amato S, Barbieri M, et al: Minoxidil (Mx) as a
prophylaxis of doxorubicin–induced alopecia. Ann Oncol 1994, 5:769–770.
19. Wang J, Lu Z, Au JL: Protection against chemotherapy-induced alopecia.
Pharm Res 2006, 23:2505–2514.
20. http://www.biobankjp.org.
21. Nakamura Y: The BioBank Japan Project. Clin Adv Hematol Oncol 2007,
5:696–697.
22. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y: A high-
throughput SNP typing system for genome-wide association studies.
J Hum Genet 2001, 46:471–477.
23. http://www.cran.r-project.org/.
24. http://pngu.mgh.harvard.edu/purcell/plink/.
Chung et al. Breast Cancer Research 2013, 15:R81 Page 10 of 10
http://breast-cancer-research.com/content/15/5/R8125. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, et al: PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet
2007, 81:559–575.
26. De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D,
Heubach JF, Sandbrink R, et al: Integration of genetic risk factors into a
clinical algorithm for multiple sclerosis susceptibility: a weighted genetic
risk score. Lancet Neurol 2009, 8:1111–1119.
27. Clapham DE: Calcium signaling. Cell 2007, 131:1047–1058.
28. Price VH: Treatment of hair loss. N Engl J Med 1999, 341:964–973.
29. Li GR, Deng XL: Functional ion channels in stem cells. World J Stem Cells
2011, 3:19–24.
30. Endo K, Takeshita T, Kasai H, Sasaki Y, Tanaka N, Asao H, Kikuchi K, Yamada
M, Chenb M, O'Shea JJ, et al: STAM2, a new member of the STAM family,
binding to the Janus kinases. FEBS Lett 2000, 477:55–61.
31. Yamada M, Ishii N, Asao H, Murata K, Kanazawa C, Sasaki H, Sugamura K:
Signal-transducing adaptor molecules STAM1 and STAM2 are required
for T-cell development and survival. Mol Cell Biol 2002, 22:8648–8658.
32. Liu J, Sun K, Bai Y, Zhang W, Wang X, Wang Y, Wang H, Chen J, Song X, Xin Y,
et al: Association of three-gene interaction among MTHFR, ALOX5AP and
NOTCH3 with thrombotic stroke: a multicenter case–control study.
Hum Genet 2009, 125:649–656.
33. Manev H, Manev R: 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene
polymorphisms as factors in vascular pathology and Alzheimer’s disease.
Med Hypotheses 2006, 66:501–503.
34. Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD,
Mirmirani P: Hair follicle stem cell-specific PPARgamma deletion causes
scarring alopecia. J Invest Dermatol 2009, 129:1243–1257.
35. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, Kim H,
Singh P, Lee A, Chen WV, et al: Genome-wide association study in
alopecia areata implicates both innate and adaptive immunity.
Nature 2010, 466:113–117.
36. Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W: Beta-Catenin
controls hair follicle morphogenesis and stem cell differentiation in the
skin. Cell 2001, 105:533–545.
37. Zhang Y, Andl T, Yang SH, Teta M, Liu F, Seykora JT, Tobias JW, Piccolo S,
Schmidt-Ullrich R, Nagy A, et al: Activation of beta-catenin signaling
programs embryonic epidermis to hair follicle fate. Development 2008,
135:2161–2172.
38. Young P, Boussadia O, Halfter H, Grose R, Berger P, Leone DP, Robenek H,
Charnay P, Kemler R, Suter U: E-cadherin controls adherens junctions in the
epidermis and the renewal of hair follicles. EMBO J 2003, 22:5723–5733.
39. Samuelov L, Sprecher E, Tsuruta D, Biro T, Kloepper JE, Paus R: P-cadherin
regulates human hair growth and cycling via canonical Wnt signaling
and transforming growth factor-beta2. J Invest Dermatol 2012,
132:2332–2341.
doi:10.1186/bcr3475
Cite this article as: Chung et al.: A genome-wide association study of
chemotherapy-induced alopecia in breast cancer patients. Breast Cancer
Research 2013 15:R81.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
